Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albumin-bound docetaxel - CSPC ZhongQi Pharmaceutical Technology

Next Previous
Drug Profile

Albumin-bound docetaxel - CSPC ZhongQi Pharmaceutical Technology

Alternative Names: CPO-100; Docetaxel albumin-bound; Docetaxel for injection (albumin-bound); Docetaxel nanoparticle formulated with human albumin - CSPC ZhongQi Pharmaceutical Technology; DTX-HSA; HB-1801

Latest Information Update: 20 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Developer Conjupro Biotherapeutics; CSPC ZhongQi Pharmaceutical Technology
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gastric cancer; HER2 positive breast cancer
  • Phase II Adenocarcinoma; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
  • Phase I/II Squamous cell cancer

Most Recent Events

  • 12 Aug 2025 CSPC ZhongQi Pharmaceutical Technology plans a phase II trial for HER2-positive breast cancer (Unresectable/Inoperable, Recurrent, Metastatic disease, First-line therapy) in September 2025 (IV, Infusion) (NCT07116824)
  • 24 Jul 2025 CSPC ZhongQi Pharmaceutical Technology plans a phase II trial for (Unresectable/Inoperable, Metastatic disease, Late-stage disease, Second-line therapy or greater) (IV, Infusion) in August 2025 (NCT07083505)
  • 04 Jun 2025 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in China (IV) (NCT06947291)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top